甘精胰岛素和格列美脲对初诊2型糖尿病疗效的比较

The effect of short-term intensive therapy with glargine versus glimepiride in newly diagnosed type 2 diabetic patients

目的对HbA1c>9%的新诊断的2型糖尿病(T2DM)患者进行甘精胰岛素或格列美脲联合二甲双胍的短期强化治疗,探讨两种强化方案的疗效。方法 36例新诊断的T2DM患者随机分为两组,每组18例,分别使用甘精胰岛素或格列美脲联合二甲双胍治疗,疗程12周,对其在治疗前后血糖控制情况及胰岛β细胞功能进行自身及组间比较。结果治疗后两组FPG、2hPG、HbA1c均显著下降(P均<0.01),HOMA-IR下降(P<0.05),HOMA-β升高(P<0.01)。FPG、2hPG、HbA1c治疗前后的差值及治疗12周后早餐前后血糖差值,两组间比较差异均有统计学意义(P均<0.05),甘精组血糖达标更迅速。结论 HbA1c>9%的新诊断的T2DM患者两种短期强化方案疗效均佳,且胰岛素组降糖更显著、迅速。

Objective To evaluate the effects of two different short-term intensive therapies on glucose control and β-cell function in newly diagnosed type 2 diabetic patients. Methods The therapeutic effects were measured after intensive therapy in each group. Results After the treatment, FPG,2hPG,HbA1c were significantly decreased（P〈0.01）in each group. HOMA-β were increased（P〈0.01） and HOMA-IR were decreased（P〈0. 05）in each group. The time of achieving optimal glycemic level was shorter and glycemic level was significantly decreased in glargine group. Conclusions The resuls suggest both short-term intensive therapies produce significant effects in newly diagnosed type 2 diabetic patients. Glargine group shows more visible and rapid therapeutic effects.